Search

Request HLA Explore Free Trial

Omixon Blog

Omixon and AGBL Partner for Extensive Middle East and North-Africa Distribution Deal

29/11/2018

Omixon and Alliance Global FZ-LLC are pleased to announce the execution of an exclusive distribution agreement to cover markets...

Events

EFI Regional Meeting, January 26, 2019

15/11/2018

The Omixon Team is back in Bucharest, Romania for the upcoming Annual EFI Region 8 & Balkan EPT Meeting!…

Facebook
Twitter

Omixon Biocomputing Solutions

Tweets by @OmixonBio

Testimonials

“Together with Omixon, we have now used next- generation sequencing tools to significantly advance HLA typing.”Prof. Dimitri Monos, The Children’s Hospital of Philadelphia
"It's disappointing sometimes how easily HLA Twin deals with challenging samples like rare alleles. The data is there - you're just convinced!" Alexandre Walencik, Biologiste Médical, Laboratoire HLA - Nantes
“We are using next-generation sequencing techniques to advance patient care at Almac and we know that accurate data and meaningful data interpretation are dependent upon employing the best analysis tools and techniques. Omixon was also the strongest performer in terms of total mutations detected with a 99.14% detection sensitivity in single end mode.”Gavin Oliver, Bioinformatics Team Leader at Almac
"The Holotype HLA method is optimally designed for the service laboratory user and is supported by a clear and easily followed protocol which facilitates method performance. Omixon is an enabling and supportive company who work with you to deliver successful outcomes for your programme rather than sales."Brendan Clarke, HLA Lab Director at Leeds St. James's University Hospital
“Omixon has developed an excellent direct genotyping method from next generation sequencing that addresses the major problems associated with HLA calling. They have developed industry-leading capabilities that we are very pleased to be able to incorporate into the informatics pipeline that powers our interpretation services offerings.”Wolfgang Daum, CEO of Knome
“NGS is rapidly being adopted by clinical and research laboratories worldwide. Easy to use analytical methods and software tools that aid the generation of accurate results are critical for the success of this ground breaking new technology.”Dr Lajos Pusztai,Professor at the University of Texas MD
Anderson Cancer Center
“Best of all, the HLA types reported were fully concordant with data obtained using SBT.”Mike Tayeb, DNA Genotek

Omixon Academy

Improve your knowledge!

Our Training Series provide ABHI accredited webinars, workshops, onsite trainings and online demo.

Contact Us

Just ask! Get answers!

Your questions and comments are important to us. We’ve got you covered.

Omixon Newsletter

Subscribe now!

Leave this field empty if you're human:

By clicking 'Ok' I accept the
Privacy Policy

Sitemap

Products

Holotype HLA™
HLA Twin™
Monotype HLA™
Monotype ABO™
HLA Explore™
Training and Field Support

Company

About
Team
Board of Directors
Scientific Advisory Board
Careers / Internships

Omixon Academy

HLA Library
HLA Twin Videos
Lab Train Me Videos
Posters
Workshops
Symposiums
Webinars
Accreditation

Contact us

Our Mailing Address:

Omixon Biocomputing Ltd.
H-1117 Budapest,
Fehérvári út 50-52.,
Hungary, EU

US Branch Office:

Omixon Inc.
One Broadway,
Cambridge,
MA 02142
USA

Support number: +1 (617) 500 0790

sales@omixon.com | www.omixon.com